Navidea Biopharmaceuticals Inc

Type: Company
Name: Navidea Biopharmaceuticals Inc
First reported 12 hours ago - Updated 12 hours ago - 1 reports

NAVIDEA BIOPHARMACEUTICALS : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.On April 21, 2014 , Navidea Biopharmaceuticals, Inc. (the "Company") entered intoan employment ... [Published 4 Traders - 12 hours ago]
First reported Apr 23 2014 - Updated Apr 23 2014 - 1 reports

Navidea Biopharmaceuticals : Posts Progress Updates on Lymphoseek Programs

Navidea Biopharmaceuticals, Inc. , a biopharmaceutical company focusing on precision diagnostic radiopharmaceuticals, provided updates on several programs and events relating to Lymphoseek (technetium Tc 99m tilmanocept) Injection, including a head-to-head ... [Published 4 Traders - Apr 23 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 3 reports

Navidea Biopharmaceuticals Provides Progress Updates on Lymphoseek(...

Navidea Biopharmaceuticals Provides Progress Updates on Lymphoseek(r) ProgramsApr. 17, 2014 Business Editors/Biotech WritersDUBLIN, Ohio--(BUSINESS WIRE)--Apr. 17, 2014--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused ... [Published Finwin - Apr 17 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 9 reports

Navidea Biopharmaceuticals Analyst Report: Long Term Market Potential Of Lymphoseek Does Not Justify Current Valuation By

/PRNewswire/ -- Navidea Pharmaceuticals, Inc. (NYSEMKT: NAVB), is a biopharmaceutical company that is focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Its core product, Lymphoseek, a small-molecule ... [Published BioSpace - Apr 11 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Navidea Pharmaceuticals Inc. Analyst Report: Long Term Market Potential of Lymphoseek does not Justify Current Valuation by BrokerBank Securities, Inc.

/PRNewswire/ -- Navidea Pharmaceuticals, Inc. (NYSEMKT: NAVB), is a biopharmaceutical company that is focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents.  Its core product, Lymphoseek, a small-molecule ... [Published Michigan Live - Apr 11 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 6 reports

Navidea Announces Presentation of Study Findings of Manocept™ Platform Imaging Agent in Kaposi Sarcoma at AACR Annual Meeting

Navidea Announces Presentation of Study Findings of Manocept™ Platform Imaging Agent in Kaposi Sarcoma at AACR Annual Meeting ... [Published Noodls - Apr 10 2014]
First reported Apr 09 2014 - Updated Apr 09 2014 - 2 reports

Navidea Continues To Execute, When Will The Stock Follow?

By Basileus:To be blunt, Navidea Biopharmaceuticals ( NAVB ) has been a poor performer over the past year. Furthermore, anyone who reasoned as I did and saw the share price movement following the Crede financing deal last October as a buying opportunity, ... [Published BioPortfolio - Apr 09 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

Navidea's PET agent featured at German nuclear medicine congress

-- Navidea Biopharmaceuticals has announced its PET imaging agent NAV4694 is the subject of several presentations at this week's German Society of Nuclear Medicine annual congress.To view the remainder of this article, and other exclusive content, you ... [Published AuntMinnieEurope - Mar 27 2014]
First reported Mar 26 2014 - Updated Mar 26 2014 - 5 reports

Navidea Announces Presentations Highlighting NAV4694 Beta-Amyloid, PET Imaging Agent at the German Society of Nuclear Medicine Congress

Navidea Announces Presentations Highlighting NAV4694 Beta-Amyloid, PET Imaging Agent at the German Society of Nuclear Medicine Congress ... [Published Noodls - Mar 26 2014]
First reported Mar 19 2014 - Updated Mar 20 2014 - 7 reports

Exact Sciences Publish Results of DeeP-C Study in NEJM; Navidea Offers Update on EMA Application For Lymphoseek

Below is a look at some of the headlines for companies that made news in the healthcare sector on March 19, 2014.Exact Sciences Corp. (Nasdaq: EXAS) announced results from its DeeP-C pivotal clinical study have been published online in the New England ... [Published BioMedReports - Mar 20 2014]
First reported Mar 06 2014 - Updated Mar 07 2014 - 6 reports

Navidea Biopharmaceuticals closes $30m loan with Oxford Finance

Navidea Biopharmaceuticals, a biopharmaceutical company, has closed a $30m non-dilutive loan transaction with Oxford Finance. ... [Published PBR - News - Mar 07 2014]
First reported Feb 04 2014 - Updated Feb 05 2014 - 11 reports

Navidea Biopharmaceuticals to Present at the 16th Annual BIO CEO and Investor Conference

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals CEO Dr. Mark Pykett will present at the BIO CEO Conference in NYC on February 10, 2014 at 1:30 PM ET. ... [Published EON Energy - Feb 04 2014]

Quotes

...of Medicine ; Director of the Comprehensive Breast Health Center ; UC San Diego Moores Cancer Center , and Principal Investigator on the study. "It is well accepted that sentinel node injection can be painful. We designed this study to try to understand if Lymphoseek injection is less painful and could improve the patient experience."
...He’s also "a little flaky. I’m betting he’s going to make a billion dollars rather than blow up."

More Content

All (129) | News (58) | Reports (0) | Blogs (69) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
NAVIDEA BIOPHARMACEUTICALS : Change in Director... [Published 4 Traders - 12 hours ago]
Navidea Biopharmaceuticals : Posts Progress Upd... [Published 4 Traders - Apr 23 2014]
Navidea Biopharmaceuticals Reports Progress of ... [Published Individual.com - Apr 22 2014]
Navidea Biopharmaceuticals Provides Progress Up... [Published Finwin - Apr 17 2014]
Navidea Biopharmaceuticals Provides Progress Up... [Published Business Wire Health News - Apr 17 2014]
Navidea Biopharmaceuticals Provides Progress Up... [Published BioPortfolio - Apr 17 2014]
Once a Notorious Short Seller, Martin Shkreli N... [Published BusinessWeek - Apr 17 2014]
Navidea Biopharmaceuticals Analyst Report: Lon... [Published BioSpace - Apr 11 2014]
Navidea Pharmaceuticals Inc. Analyst Report: Lo... [Published Biotechgate - Apr 11 2014]
Navidea Pharmaceuticals Inc. Analyst Report:  L... [Published PharmaDiversity - Apr 11 2014]
Navidea Pharmaceuticals Inc. Analyst Report Lo... [Published BioPortfolio - Apr 11 2014]
Navidea Pharmaceuticals Inc. Analyst Report: L... [Published Individual.com - Apr 11 2014]
Navidea Pharmaceuticals Inc. Analyst Report: Lo... [Published Yahoo! Finance - Apr 11 2014]
Navidea Pharmaceuticals Inc. Analyst Report: Lo... [Published Finwin - Apr 11 2014]
Navidea Pharmaceuticals Inc. Analyst Report: Lo... [Published Digital Journal - Apr 11 2014]
Navidea Pharmaceuticals Inc. Analyst Report: L... [Published PR Newswire - Apr 11 2014]
Navidea Pharmaceuticals Inc. Analyst Report: Lo... [Published Michigan Live - Apr 11 2014]
Navidea Announces Presentation of Study Finding... [Published Noodls - Apr 10 2014]
Study CD206targeting Manocept platform may prov... [Published BioPortfolio - Apr 10 2014]
Navidea Announces Presentation of Study Finding... [Published HispanicBusiness.com - Apr 10 2014]
Navidea Announces Presentation of Study Finding... [Published Nasdaq - Apr 10 2014]
Navidea Announces Presentation of Study Finding... [Published EON Science - Apr 10 2014]
Navidea Announces Presentation of Study Finding... [Published Business Wire Science: Science News - Apr 10 2014]
Navidea Announces Presentation of Study Finding... [Published Business Wire Health News - Apr 10 2014]
Navidea Continues To Execute, When Will The Sto... [Published BioPortfolio - Apr 09 2014]
Navidea Continues To Execute, When Will The Sto... [Published Seeking Alpha - Apr 09 2014]
Global Radiopharmaceuticals Market Insight [Published TickerTech.com - Apr 01 2014]
Navidea's PET agent featured at German nuclear ... [Published AuntMinnieEurope - Mar 27 2014]
Navidea Announces Presentations Highlighting NA... [Published Noodls - Mar 26 2014]
Navidea Announces Presentations Highlighting NA... [Published Finwin - Mar 26 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Navidea Biopharmaceuticals Provides Progress Up... [Published Business Wire Health News - Apr 17 2014]
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea provided updates on several programs and events relating to Lymphoseek including a head-to-head clinical study underway at the UCSD. ...
Navidea Announces Presentation of Study Finding... [Published EON Science - Apr 10 2014]
DUBLIN, Ohio--(EON: Enhanced Online News)--Navidea announces presentation at AACR by UCSF researchers on the potential utility of Manocept platform imaging agents in identifying affected tissues and lymph nodes in patients with Kaposi Sarcoma. ...
Navidea Announces Presentation of Study Finding... [Published Business Wire Science: Science News - Apr 10 2014]
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea announces presentation at AACR by UCSF researchers on the potential utility of Manocept platform imaging agents in identifying affected tissues and lymph nodes in patients with Kaposi Sarcoma. ...
Navidea Announces Presentation of Study Finding... [Published Business Wire Health News - Apr 10 2014]
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea announces presentation at AACR by UCSF researchers on the potential utility of Manocept platform imaging agents in identifying affected tissues and lymph nodes in patients with Kaposi Sarcoma. ...
Navidea Announces Presentations Highlighting NA... [Published Business Wire Health News - Mar 26 2014]
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea collaborators from the Department of Nuclear Medicine at University Hospital of Leipzig are presenting highlights of PET imaging agent, NAV4694, at the German Society of Nuclear Medicine. ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Pre-Market Breakdown: Hologic, Navidea Biopharm... [Published Financial Services - Dec 17 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.